ARTICLE | Company News
Bridge Biotherapeutics gets rights to kinase inhibitor from Korea Research Institute
February 1, 2019 7:33 PM UTC
Korea Research Institute of Chemical Technology (Daejeon, South Korea) granted Bridge Biotherapeutics Inc. (Seongnam, South Korea) exclusive, worldwide rights to an undisclosed kinase inhibitor...